Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting a -5.54% change compared to its last close.

zacks.com - 2026-07-10 18:46:10

Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX's potential valuation in a rapidly expanding GLP-1 market.

seekingalpha.com - 2026-07-10 11:50:47

Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or decisive breakout above major resistance will likely determine the next trend.

fxempire.com - 2026-07-09 17:34:29

Viking Therapeutics (VKTX +2.28%) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries serious risk, especially as a better-funded rival gains a head start.

fool.com - 2026-07-09 15:00:00

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

zacks.com - 2026-07-09 11:01:20

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.

247wallst.com - 2026-07-09 08:00:59

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.

zacks.com - 2026-07-08 18:51:14

A deepening sell-off in chip and memory stocks dragged all four major U.S. equity indexes lower by midday Tuesday.

benzinga.com - 2026-07-07 13:20:32

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

fool.com - 2026-07-07 10:36:52

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

fool.com - 2026-07-06 07:35:01

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

fool.com - 2026-07-06 07:15:00

Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of pharma juggernauts.

fool.com - 2026-07-05 01:05:00

Viking Therapeutics is studying its weight loss drug candidate in late-stage trials. If all goes smoothly, the biotech could enter a market nearing $100 billion in the next few years.

fool.com - 2026-07-04 05:10:00

Viking's VK2735 has advantages over other weight-loss drugs, and investors anticipate positive results from Phase 3 trials in the coming years. The development of VK2735 as a dual formulation therapy could be the key to unlocking value for investors.

fool.com - 2026-07-03 09:25:39

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.

zacks.com - 2026-07-01 18:51:10

Viking Therapeutics' pipeline includes several promising weight-loss candidates. The stock could soar in the next 18 months, but there is plenty of risk involved.

fool.com - 2026-07-01 14:00:00

Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).

seekingalpha.com - 2026-06-30 14:32:38

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

zacks.com - 2026-06-29 12:11:09

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

zacks.com - 2026-06-29 10:31:10

Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.

fool.com - 2026-06-29 04:44:00

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

fool.com - 2026-06-26 11:05:48

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.

zacks.com - 2026-06-25 18:45:39

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

zacks.com - 2026-06-25 11:01:18

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss.

prnewswire.com - 2026-06-24 07:05:00

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of promise in clinical trials.

fool.com - 2026-06-23 10:14:00

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

247wallst.com - 2026-06-23 07:55:41

Viking Therapeutics is running phase 3 studies for its leading anti-obesity candidate. Its shares could soar from current levels, provided everything goes according to plan.

fool.com - 2026-06-23 00:30:00

Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinical trials.

fool.com - 2026-06-22 20:15:00

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $30.29, indicating a +2.16% shift from the previous trading day.

zacks.com - 2026-06-17 18:50:22

Viking is developing candidates in the high-growth weight loss drug market. The company's lead candidate is involved in late-stage studies.

fool.com - 2026-06-12 01:15:00

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. Chen, M.D.

prnewswire.com - 2026-06-11 07:05:00

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.

zacks.com - 2026-06-10 18:50:18

The global market for drugs that treat obesity could be worth $150 billion by 2035. Viking Therapeutics is developing a pill and an injectable version of its weight-loss candidate.

fool.com - 2026-06-10 13:27:00

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

zacks.com - 2026-06-10 13:01:19

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.

zacks.com - 2026-06-04 18:45:30

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-04 15:32:55

Eli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market. Investors are hoping Viking's VK2735 will prove efficacious and safe in its Phase 3 clinical trials.

fool.com - 2026-06-03 06:49:00

An upcoming trial result could change how investors think about the weight-loss drug market.

fool.com - 2026-06-02 10:48:00

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

fool.com - 2026-05-30 06:15:00

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-29 12:31:56

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.

zacks.com - 2026-05-28 18:46:05

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins

247wallst.com - 2026-05-26 08:50:16

These players are seeing exciting results in clinical trials.

fool.com - 2026-05-26 04:04:00

Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches.

fool.com - 2026-05-25 20:00:00

Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.

fool.com - 2026-05-23 16:31:00

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

zacks.com - 2026-05-21 12:36:08

Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.

fool.com - 2026-05-21 08:10:00

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows: William Blair 46th Annual Growth Stock Conference Details: Viking management will deliver a corporate presentation, followed by a breakout session, and participate in investor meetings.Conference Dates: June 2-4, 2026Presentation Date/Time: Tuesday, June 2nd at 2:00 pm – 2:30 pm CTBreakout session: Tuesday, June 2nd at 2:40 pm – 3:10 pm CTLocation: Chicago, IL Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.

prnewswire.com - 2026-05-21 07:05:00

Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.

fool.com - 2026-05-20 23:15:00

There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.

fool.com - 2026-05-18 20:45:00